HLB Science Merger with HLB Confirmed with 99% Shareholder Approval

HLB Science shareholders approve merger with HLB. (Photo courtesy of IT Times)

 

On November 13, HLB Science announced that its shareholders approved the merger with HLB at an extraordinary general meeting in Seoul, with 99% voting in favor. Under the agreement, HLB will remain the surviving company with a merger ratio of 1 to 0.0446318, and HLB Science will be dissolved.

 

The unified company aims to combine HLB’s oncology expertise with HLB Science’s peptide-based discovery technology, expanding its pipeline into sepsis, metabolic, and immune diseases. Development of the sepsis treatment candidate DD-S025P is expected to accelerate, with an IND filing to the U.S. FDA planned within the year, alongside global licensing opportunities. The merger is also expected to enhance operational efficiency, reduce redundancies, and strengthen financial stability.

IT Times: https://www.ittimes.com/news/articleView.html?idxno=81600

HLB and HLB Science Merger Approved, Unified Entity to Launch on December 31 - IT타임스